TISIDB

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF00365 Phosphofructokinase
Function	Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis (PubMed:22923583). Negatively regulates the phagocyte oxidative burst in response to bacterial infection by controlling cellular NADPH biosynthesis and NADPH oxidase-derived reactive oxygen species. Upon macrophage activation, drives the metabolic switch toward glycolysis, thus preventing glucose turnover that produces NADPH via pentose phosphate pathway (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0002792 negative regulation of peptide secretion GO:0005996 monosaccharide metabolic process GO:0006002 fructose 6-phosphate metabolic process GO:0006006 glucose metabolic process GO:0006007 glucose catabolic process GO:0006090 pyruvate metabolic process GO:0006091 generation of precursor metabolites and energy GO:0006096 glycolytic process GO:0006165 nucleoside diphosphate phosphorylation GO:0006732 coenzyme metabolic process GO:0006733 oxidoreduction coenzyme metabolic process GO:0006734 NADH metabolic process GO:0006735 NADH regeneration GO:0006757 ATP generation from ADP GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009132 nucleoside diphosphate metabolic process GO:0009135 purine nucleoside diphosphate metabolic process GO:0009141 nucleoside triphosphate metabolic process GO:0009144 purine nucleoside triphosphate metabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009179 purine ribonucleoside diphosphate metabolic process GO:0009185 ribonucleoside diphosphate metabolic process GO:0009199 ribonucleoside triphosphate metabolic process GO:0009205 purine ribonucleoside triphosphate metabolic process GO:0009306 protein secretion GO:0009743 response to carbohydrate GO:0009746 response to hexose GO:0009749 response to glucose GO:0009914 hormone transport GO:0010817 regulation of hormone levels GO:0015833 peptide transport GO:0016052 carbohydrate catabolic process GO:0019318 hexose metabolic process GO:0019320 hexose catabolic process GO:0019362 pyridine nucleotide metabolic process GO:0019674 NAD metabolic process GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030073 insulin secretion GO:0030388 fructose 1,6-bisphosphate metabolic process GO:0034284 response to monosaccharide GO:0042278 purine nucleoside metabolic process GO:0042886 amide transport GO:0044282 small molecule catabolic process GO:0044723 single-organism carbohydrate metabolic process GO:0044724 single-organism carbohydrate catabolic process GO:0046031 ADP metabolic process GO:0046034 ATP metabolic process GO:0046128 purine ribonucleoside metabolic process GO:0046365 monosaccharide catabolic process GO:0046496 nicotinamide nucleotide metabolic process GO:0046676 negative regulation of insulin secretion GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0046888 negative regulation of hormone secretion GO:0046939 nucleotide phosphorylation GO:0050708 regulation of protein secretion GO:0050709 negative regulation of protein secretion GO:0050796 regulation of insulin secretion GO:0051048 negative regulation of secretion GO:0051051 negative regulation of transport GO:0051186 cofactor metabolic process GO:0051224 negative regulation of protein transport GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:0061615 glycolytic process through fructose-6-phosphate GO:0061620 glycolytic process through glucose-6-phosphate GO:0061621 canonical glycolysis GO:0061718 glucose catabolic process to pyruvate GO:0072524 pyridine-containing compound metabolic process GO:0090087 regulation of peptide transport GO:0090276 regulation of peptide hormone secretion GO:0090278 negative regulation of peptide hormone secretion GO:1901657 glycosyl compound metabolic process GO:1903531 negative regulation of secretion by cell GO:1904950 negative regulation of establishment of protein localization
Molecular Function	GO:0003872 6-phosphofructokinase activity GO:0008443 phosphofructokinase activity GO:0019200 carbohydrate kinase activity GO:0030246 carbohydrate binding GO:0048029 monosaccharide binding GO:0070061 fructose binding GO:0070095 fructose-6-phosphate binding
Cellular Component	GO:0005945 6-phosphofructokinase complex GO:0044445 cytosolic part GO:0061695 transferase complex, transferring phosphorus-containing groups

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03018 RNA degradation hsa04066 HIF-1 signaling pathway hsa04152 AMPK signaling pathway hsa04922 Glucagon signaling pathway hsa00010 Glycolysis / Gluconeogenesis hsa00030 Pentose phosphate pathway hsa00051 Fructose and mannose metabolism hsa00052 Galactose metabolism hsa01100 Metabolic pathways hsa01200 Carbon metabolism hsa01230 Biosynthesis of amino acids
Reactome	R-HSA-70326: Glucose metabolism R-HSA-70171: Glycolysis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates R-HSA-6798695: Neutrophil degranulation

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PFKL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PFKL in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PFKL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.064	0.766
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.155	0.955
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.223	0.912
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.521	0.186
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.368	0.889
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.716	0.832
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.033	0.937
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.057	0.975
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.034	0.987
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.254	0.907
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.583	0.857
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.146	0.0536

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PFKL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	4.1	3.3	0.61
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	5.1	2.3	0.647
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	50	14.3	35.7	0.491
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PFKL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PFKL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PFKL. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PFKL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PFKL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PFKL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PFKL
Name	phosphofructokinase, liver
Aliases	PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location	21q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PFKL collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PFKL